NCT02220998 - Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection | Biotech Hunter

Enrollment

269

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

September 30, 2015

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL

SOF/VEL (400/100 mg) FDC tablet administered orally once daily

DRUG

SOF

SOF 400 mg tablet administered orally once daily

DRUG

RBV

RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (51)

10021

New York

10029

New York

10468

The Bronx

11021

Great Neck

15213

Pittsburgh

15240

Pittsburgh

19104

Philadelphia

21093

Lutherville

21205

Baltimore

23226

Richmond

23298

Richmond

23502

Norfolk

28801

Asheville

30060

Marietta

30308

Emory university, Atlanta

Atlanta

32256

Jacksonville

32803

Orlando

33136

Miami

33414

Wellington

34205

Bradenton

37211

Nashville

38138

Germantown

46237

Indianapolis

48202

Detroit

60611

Chicago

60637

Chicago

63104

St Louis

71280

Monroe

76012

Arlington

78215

San Antonio

80045

Aurora

87505

Santa Fe

90027

Los Angeles

90036

Los Angeles

90048

Los Angeles

90057

Los Angeles

90073

Los Angeles

90822

Long Beach

91105

Pasadena

92103

San Diego

92123

San Diego

92154

San Diego

94110

San Francisco

94118

San Francisco

94304

Palo Alto

95817

Sacramento

32610-0272

Gainesville

02129

Boston

02905

Providence

00909

San Juan